JP2023507408A5 - - Google Patents

Info

Publication number
JP2023507408A5
JP2023507408A5 JP2022537311A JP2022537311A JP2023507408A5 JP 2023507408 A5 JP2023507408 A5 JP 2023507408A5 JP 2022537311 A JP2022537311 A JP 2022537311A JP 2022537311 A JP2022537311 A JP 2022537311A JP 2023507408 A5 JP2023507408 A5 JP 2023507408A5
Authority
JP
Japan
Prior art keywords
less
approximately
dose
pabra
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537311A
Other languages
English (en)
Japanese (ja)
Other versions
JP7744344B2 (ja
JP2023507408A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065655 external-priority patent/WO2021127210A1/en
Publication of JP2023507408A publication Critical patent/JP2023507408A/ja
Publication of JP2023507408A5 publication Critical patent/JP2023507408A5/ja
Application granted granted Critical
Publication of JP7744344B2 publication Critical patent/JP7744344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537311A 2019-12-18 2020-12-17 神経系疾患および障害を改善するための方法 Active JP7744344B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962950077P 2019-12-18 2019-12-18
US62/950,077 2019-12-18
US202063034364P 2020-06-03 2020-06-03
US63/034,364 2020-06-03
PCT/US2020/065655 WO2021127210A1 (en) 2019-12-18 2020-12-17 Methods for improving neurological diseases and disorders

Publications (3)

Publication Number Publication Date
JP2023507408A JP2023507408A (ja) 2023-02-22
JP2023507408A5 true JP2023507408A5 (enExample) 2023-12-08
JP7744344B2 JP7744344B2 (ja) 2025-09-25

Family

ID=76437605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537311A Active JP7744344B2 (ja) 2019-12-18 2020-12-17 神経系疾患および障害を改善するための方法

Country Status (6)

Country Link
US (3) US11607395B2 (enExample)
EP (1) EP4076422A4 (enExample)
JP (1) JP7744344B2 (enExample)
AU (1) AU2020405091B2 (enExample)
CA (1) CA3161376A1 (enExample)
WO (1) WO2021127210A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法
US12616667B2 (en) * 2021-11-15 2026-05-05 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
CN115212194B (zh) * 2022-01-07 2024-08-13 中南大学湘雅三医院 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
CN116212002A (zh) * 2022-01-14 2023-06-06 中南大学湘雅三医院 一种预防或治疗缺血/再灌注损伤的药物组合物及应用
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
WO2023225021A1 (en) * 2022-05-17 2023-11-23 Curasen Therapeutics, Inc. Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US20260207533A1 (en) * 2022-12-21 2026-07-23 Curasen Therapeutics, Inc. Methods for treating various conditions and indications with agonists and antagonists
CN120583945A (zh) 2023-01-20 2025-09-02 阿托基公司 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025188807A1 (en) * 2024-03-06 2025-09-12 Curasen Therapeutics, Inc. Combination compositions and methods of use
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541188A (en) * 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
US7135497B1 (en) 2000-07-07 2006-11-14 New York Medical College Treating neural conditions resulting from spinal cord contusions and other causes
AU2003251949A1 (en) 2002-07-18 2004-02-09 Vanderbilt University Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype
CA2544611A1 (en) 2003-10-09 2005-04-21 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
US9492114B2 (en) 2004-06-18 2016-11-15 Banner Health Systems, Inc. Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease
US7528175B2 (en) 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
EP1754474A1 (en) 2005-02-02 2007-02-21 Eucro European Contract Research GmbH & Co. KG Use of S-Clenbuterol
US20080033027A1 (en) 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
WO2006108424A2 (en) 2005-04-13 2006-10-19 Astion Pharma A/S Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
US20070021421A1 (en) 2005-07-25 2007-01-25 Hampton Thomas G Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis
SI1924264T1 (sl) * 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
CA2732513C (en) 2008-08-01 2017-04-25 Arca Biopharma, Inc. Methods and compositions involving (s)-bucindolol
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011133226A2 (en) * 2010-04-22 2011-10-27 The Board Of Trustees Of The Leland Stanford Junior University Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
EP2696849A4 (en) 2011-04-13 2014-10-29 Revalesio Corp COMPOSITIONS AND METHODS FOR INHIBITING AND / OR MODULATING EFFECTOR CELLS IN INFLAMMABLE NEURODEGENERATIVE ILLNESSES
US9784001B1 (en) 2011-05-03 2017-10-10 Paul Kristen, Inc Adjustable scaffolding suspension assembly
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
US20140256822A1 (en) 2013-03-11 2014-09-11 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US10111879B2 (en) 2013-06-27 2018-10-30 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
AU2014287418A1 (en) 2013-07-08 2016-01-28 Auspex Pharmaceuticals, Inc. Dihydroxyphenyl neurotransmitter compounds, compositions and methods
WO2015126915A2 (en) 2014-02-18 2015-08-27 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and social behavior in humans having deficits therein due to neurological disorders and compounds and compositions therefor
ES2864079T3 (es) * 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
US9889087B2 (en) 2014-06-10 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor
US10195198B2 (en) * 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
TWI728953B (zh) * 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
EP3398614B1 (en) 2015-12-29 2021-07-28 Kyoto University Agent for preventing and/or treating alzheimer's disease
BR112018073227A2 (pt) 2016-05-13 2019-02-19 The Board Of Trustees Of The Leland Stanford Junior University compostos moduladores do receptor adrenérgico e métodos de uso do mesmo
WO2018195473A1 (en) 2017-04-20 2018-10-25 The Brigham And Women's Hospital, Inc. Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
US20220401415A1 (en) 2019-10-25 2022-12-22 Curasen Therapeutics, Inc. Methods for treating neurological disorders with alpha1a-ar partial agonists
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP7734700B2 (ja) 2020-06-04 2025-09-05 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニストの形態及び組成物
WO2023225021A1 (en) * 2022-05-17 2023-11-23 Curasen Therapeutics, Inc. Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)

Similar Documents

Publication Publication Date Title
JP2021527712A5 (enExample)
Bakshi et al. High‐resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis
JP7744344B2 (ja) 神経系疾患および障害を改善するための方法
JP7265990B2 (ja) 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
US20040122090A1 (en) Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2004515477A (ja) Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法
Tsuchiya et al. Rapidly progressive aphasia and motor neuron disease: a clinical, radiological, and pathological study of an autopsy case with circumscribed lobar atrophy
US20120123164A1 (en) Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
JPH08500093A (ja) 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
JP2021527711A5 (enExample)
JP2023541379A5 (enExample)
CA2139000A1 (en) Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
JP2025163203A (ja) ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン
Battistin et al. Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine
CN107847504A (zh) 淀粉状蛋白β的加兰他敏清除
AU2015258814A1 (en) Clearance of amyloid ss
Fowler et al. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain
JP2005523269A (ja) 老人性うつ病の治療におけるカルニチン
Huang et al. Tau PET with 18F-THK-5351 Taiwan patients with familial Alzheimer's disease with the APP P. D678H mutation
JP2021530568A5 (enExample)
JP7121859B2 (ja) 安息香酸塩または安息香酸誘導体を含む、抗ｎ－メチル－ｄ－アスパラギン酸受容体脳炎を予防または治療するための医薬組成物
JP2024508052A (ja) 認知障害の治療のための化合物
CN111617255B (zh) 用于治疗中枢神经系统紊乱的组合疗法
JP5042425B2 (ja) 機能性胃腸疾患治療用トラマドール
WO2024137478A1 (en) Methods for treating various conditions and indications with agonists and antagonists